Unasnemab (MT-3921), a humanized IgG1 monoclonal antibody, targets repulsive guidance molecule A (RGMa) to enhance locomotor function and support neuroregeneration, showing potential for spinal cord injury research [1].
Target:
rH116A3 , MT-3921
* VAT and and shipping costs not included. Errors and price changes excepted
